The best strategy for managing patients with resolved hepatitis B virus infection (HBsAg negative, anti-HBc antibodies positive with or without anti-HBs antibodies) and hematological malignancies under immunosuppressive therapies has not been defined. The aim of this study was to prospectively analyze the risk of hepatitis B virus reactivation in these patients.
Pompili, M., Basso, M., Hohaus, S., Bosco, G., Nosotti, L., D'Andrea, M. L., Fenu, S., Grieco, A., Laurenti, L., Mirisola, C., Pagano, L., Rapaccini, G. L., Sica, S., Storti, S., Landolfi, R., Prospective study of hepatitis B virus reactivation in patients with hematological malignancies, <<ANNALS OF HEPATOLOGY>>, 2015; 14 (2): 168-174. [doi:10.1016/s1665-2681(19)30778-1] [http://hdl.handle.net/10807/67246]
Prospective study of hepatitis B virus reactivation in patients with hematological malignancies
Pompili, Maurizio;Basso, Maria;Hohaus, Stefan;Bosco, Giulia;D'Andrea, Maria Luisa;Grieco, Antonio;Laurenti, Luca;Pagano, Livio;Rapaccini, Gian Ludovico;Sica, Simona;Storti, Sergio;Landolfi, Raffaele
2015
Abstract
The best strategy for managing patients with resolved hepatitis B virus infection (HBsAg negative, anti-HBc antibodies positive with or without anti-HBs antibodies) and hematological malignancies under immunosuppressive therapies has not been defined. The aim of this study was to prospectively analyze the risk of hepatitis B virus reactivation in these patients.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
